Palatin Announces Two Presentations at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Positive clinical data from its Phase 2 study of PL9643 in dry eye disease
Pre-clinical data with melanocortins for retinal inflammation
News provided by
Share this article
Share this article
CRANBURY, N.J., April 20, 2021 /PRNewswire/ Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, today announced two presentations of the Company s melanocortin platform, including PL9643 in dry eye disease, at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting, being held virtually May 1-7, 2021.
QBiotics Welcomes TDM Growth Partners As Cornerstone Investor in a Capital Raise To Accelerate Drug Development Timelines
QBiotics welcomes TDM Growth Partners as cornerstone investor
TDM Growth Partners is investing A$50 million into QBiotics to accelerate QBiotics’ human drug development pipeline, support marketing of the company’s veterinary pharmaceutical STELFONTA® and strengthen the QBiotics team
QBiotics plans to give existing shareholders the opportunity to invest at the same offer price as TDM
BRISBANE, Australia, March 16, 2021 /PRNewswire/ – QBiotics Group Limited, a life sciences company developing novel anticancer and wound healing pharmaceuticals, is pleased to announce a A$50 million placement of fully paid ordinary shares to TDM Growth Partners as a new cornerstone investor into the company. QBiotics plans to give existing shareholders the opportunity to invest at the same offer price as TDM.
(2)
- Vaccine Candidate Previously Demonstrated Antibodies and T-cell Response in Mouse Models
- Clinical Trial to Serve as Initial Validation of LinearDNA Platform in Large Mammals with Potential Advantages in Manufacturing, Storage, and Distribution over Other Vaccines Applied DNA Sciences, Inc. (NASDAQ: APDN) (the Company ), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, and its program development partner, Evvivax, S.R.L. ( Evvivax ), today announced the initiation of Phase I of a two-phase clinical trial to evaluate a LinearDNA COVID-19 vaccine candidate for the feline veterinary market. The goal of the trial is to evaluate the vaccine candidate as a strategy for the prevention of SARS-CoV-2, the virus that causes COVID-19, in feline companions of humans that may mitigate the animals as a potential reservoir for infections in humans. If successful, the clinical trial will also serve as an important initial validation of LinearDNA, Applied DNA s la
where a lot of the cancer cells count on that and in order to grow and spreading and metastasize. it s important, a new finding. more important is we always knew that mmp is responsible for some of this and new we re finding out it causes growth of the cancer locally, not the just the spread, but locally and this is a new finding and we re also seeing in the study that the mmp 10, is not found in normal tissue, but found in more cancer cells, a great finding and in mouse models, research. they found when they stop the gene, all of a sudden the cancer cells are really going to stop growing, a lot of great findings coming out as a result of this. as a result of this, how does this differ from chemotherapy? what will it do? and chemotherapy is what they usually use. and if they re using this gene, how might it help? the way it works, the cancer stem cells and tumor cells. a lot of the authorities they re using today the.